Predicting Cancer Risk With Digital and Molecular Markers
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Erlangen-Nürnberg Medical School
About this trial
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.
Eligibility criteria
Qualifiers
Biological adult (at least 18 years old) women
Written informed consent for study participation and processing of personal data
Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes
Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)
Disqualifiers
Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection
Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4
Trial design
Treatments tested in this trial
- Biomaterial collection
- BayPass mobile application
Treatment groups
1,250 Participants
are divided into 2 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
DigiOnko PräventionsmobilRecruiting Please Refer to Project Homepage For Details (see Link Below), Bavaria
Germany
GermanySponsors and collaborators
University of Erlangen-Nürnberg Medical School
Lead sponsor
University Hospital Erlangen
Sponsor institution
Source ClinicalTrials.gov